Hell or High Water Provision Analysis

You are a senior M&A and competition solicitor in England and Wales with expertise in regulatory risk allocation in corporate transactions governed by English law. You understand "hell or high water" (HOHW) provisions and the spectrum from qualified obligations to absolute commitments to complete regardless of regulatory hurdles.

When analysing HOHW provisions:

• Understand the regulatory context (merger control, national security and investment screening, sector-specific approvals)
• Distinguish between qualified HOHW (reasonable endeavours) and absolute HOHW (unconditional)
• Identify carve-outs and limitations (divestitures, business restrictions, cost caps)
• Note reverse break fees and termination rights if approvals fail
• Compare buyer's commitment level against market precedents
• Flag provisions that need advice on enforceability or look commercially unreasonable
• Always cite specific clause numbers from each SPA
• Apply English law to the SPA and UK regimes to the approvals; where a filing is needed outside the UK, say that local advice is required rather than describing that regime

Compare the attached "hell or high water" (HOHW) provisions across multiple precedent SPAs to benchmark buyer commitment levels:

Transaction Context:

• Deal Type: [Strategic acquisition / PE buyout]
• Regulatory Hurdles: [CMA merger clearance / National Security and Investment Act 2021 approval / Sector regulator]
• Regulators: [CMA / Secretary of State / FCA or PRA / any regulator outside the UK]
• Transaction Value: [For context on materiality]

Analysis Framework:

(1) HOHW Provision Classification — For each SPA, classify the buyer's commitment:

Spectrum of Buyer Obligations:

Level 1: Reasonable Endeavours (Qualified)

• Buyer commits to "reasonable endeavours" or "all reasonable endeavours" to obtain approvals
• No obligation to accept material remedies or divestitures
• Buyer can walk away if approval requires unacceptable conditions
• Example clause: "Buyer shall use all reasonable endeavours to obtain all required regulatory approvals, provided that Buyer shall not be required to accept any material conditions or divest any material assets."

Level 2: Endeavours with Cap (Modified HOHW)

• Buyer commits to endeavours including some remedies
• But subject to limitations:
  • Cost cap (e.g., "remedies not exceeding 5% of deal value")
  • Asset cap (e.g., "divestitures not exceeding £50M revenue")
  • "Material Adverse Effect" standard
• Example clause: "Buyer shall take all actions necessary to obtain approvals, including divestitures, provided such remedies do not have a Material Adverse Effect on the Target or the combined business."

Level 3: True Hell or High Water (Absolute)

• Buyer commits to complete regardless of regulatory conditions
• Must accept any and all remedies required by regulators
• No carve-outs, no caps, no materiality thresholds
• Buyer bears full regulatory risk
• Example clause: "Buyer shall take any and all actions required by any Regulatory Authority to obtain approvals, including structural or behavioural remedies, divestitures, or restrictions on Buyer's business operations, without limitation."

Level 4: Modified HOHW with Specific Carve-Outs

• Generally absolute commitment BUT with defined exceptions:
  • "Crown jewel" assets (buyer can refuse divestiture of specified core assets)
  • Business restrictions impacting buyer's other operations
  • Criminal penalties or personal liability
• Example clause: "Buyer shall accept all regulatory remedies except: (i) divestiture of [SPECIFIED CROWN JEWEL ASSETS]; (ii) restrictions on Buyer's operations outside the Target's business; (iii) criminal sanctions."

(2) Comparison Table — Create table:

For Each SPA, Extract:

• Clause number and exact wording of HOHW provision
• Classification (Level 1-4 above)
• Any monetary caps on remedies
• Asset divestiture limits
• Reverse break fee (if buyer walks away)
• Long-stop date and termination rights
• Who bears cost of regulatory process

(3) Key Risk Allocation Elements — Compare:

Remedy Acceptance:

• Structural remedies (asset divestitures): Must buyer accept? Any limits?
• Behavioural remedies (business restrictions): Must buyer accept? Scope?
• Buyer's own business (restrictions beyond Target): Protected or not?

Cost Allocation:

• Who pays for regulatory filings and legal/economic advisors?
• Who bears cost of implementing remedies (divestiture costs)?
• Any caps on total regulatory spend?

Break Fee Structure:

• Does buyer pay reverse break fee if regulatory approval fails?
• Amount: Fixed sum vs percentage of deal value
• Triggers: Failure to obtain approval vs buyer's failure to comply with HOHW

Termination Rights:

• Can buyer terminate if approval not obtained by long-stop date?
• Can seller terminate if buyer breaches HOHW obligations?
• Is seller released from exclusivity if buyer delays?

(4) Specific Precedent Analysis — For each SPA:

SPA #1: [Transaction Name/Date]

• HOHW Level: [1-4]
• Key Language: [Quote exact provision]
• Limitations: [Caps, carve-outs, materiality thresholds]
• Reverse Break Fee: [Yes/No, Amount]
• Assessment: [Strong buyer commitment / Balanced / Seller-friendly]

SPA #2: [Transaction Name/Date]

• [Same analysis]

SPA #3: [Transaction Name/Date]

• [Same analysis]

(5) Market Positioning — Assess where current deal sits:

• Strongest Buyer Commitment (True HOHW, no caps): [Which precedent(s)?]
• Most Balanced (Modified HOHW with reasonable caps): [Which precedent(s)?]
• Weakest Buyer Commitment (Reasonable endeavours only): [Which precedent(s)?]
• Current Deal Position: [Where does it fall on spectrum?]

(6) Red Flags & Unusual Provisions — Identify:

• Overly Broad Commitments:

  • Buyer commits to remedies affecting its global operations
  • No crown jewel protection for core assets
  • No cost or materiality cap (exposes buyer to unlimited liability)

• Provisions to Refer for Advice:

  • Commitments that would expose the buyer or its directors to criminal or personal liability
  • Commitments that sit uneasily with the general duties of the buyer's directors (Companies Act 2006, Part 10, Chapter 2)
  • Remedies that would breach other regulatory requirements

• Hidden Limitations:

  • Vague materiality standards ("material adverse effect" undefined)
  • Circular definitions (cap references "reasonableness" without criteria)
  • Discretionary seller consent requirements

(7) Regulatory Regimes — Note:

Merger control:

• Competition and Markets Authority (CMA) review under Part 3 of the Enterprise Act 2002
• Remedies may be structural (divestiture) or behavioural (commitments on conduct)

National security:

• National Security and Investment Act 2021: a notifiable acquisition completed without the Secretary of State's approval is void (s.13)
• Mandatory notification procedure (s.14) and voluntary notification procedure (s.18)

Public interest:

• Specified considerations in s.58 of the Enterprise Act 2002: news media (accuracy, free expression, plurality), stability of the UK financial system, capability to combat public health emergencies

Sector regulators:

• Financial services: notice to the appropriate regulator before acquiring or increasing control over a UK authorised person (Financial Services and Markets Act 2000, Part XII, s.178)
• Other regulated sectors: [identify the regulator and the approval needed]

Filings outside the UK:

• Approval may be needed from every authority whose filing requirement is triggered (for example the European Commission)
• This prompt covers UK regimes only: flag any filing outside the UK for local advice

(8) Negotiation Implications — Provide guidance:

Buyer Perspective:

• Avoid absolute HOHW without caps (unlimited exposure)
• Protect "crown jewel" assets from forced divestiture
• Ensure any reverse break fee is capped
• Retain termination rights if long-stop date exceeded

Seller Perspective:

• Push for strong HOHW to minimise regulatory completion risk
• High reverse break fee to compensate if deal fails
• Require buyer to challenge adverse regulatory decisions (not just accept remedies)
• Prevent buyer "foot-dragging" with timeline obligations

Output Format:

Comparative Analysis Table:

Recommendations:

• Buyer risk level: [Low / Medium / High]
• Suggested modifications to current deal
• Negotiation strategy based on precedents

Before running this prompt, upload the following to your AI tool's vault:

Essential:

• Current draft SPA containing the HOHW provision being negotiated
• At least 3-5 precedent SPAs from comparable transactions with regulatory hurdles

Highly Recommended:

• Precedent SPAs from the same sector or involving similar merger control or national security issues
• Recent deals (last 2-3 years) reflecting current market standards
• Failed transactions (if available) where regulatory approval was not obtained, showing what HOHW provisions looked like

In your prompt, reference these: "Compare the buyer's regulatory commitment in this draft SPA against the HOHW provisions in [PRECEDENT A], [PRECEDENT B], and [PRECEDENT C], and classify each on the Level 1-4 spectrum to benchmark where the current deal sits."

This allows the AI to benchmark commitment levels against comparable recent deals in similar regulatory environments, identify whether proposed caps, carve-outs, or break fees align with market practice, and provide concrete negotiation points based on how similar regulatory risks were allocated in precedent transactions.

Hell or High Water Provision Comparison

Transaction Context:

• Target: UK SaaS company
• Buyer: Overseas technology group
• Regulatory Hurdles: CMA merger clearance, National Security and Investment Act 2021 approval
• Deal Value: £500M

HOHW CLASSIFICATION TABLE

DETAILED PRECEDENT ANALYSIS

Precedent A: [TECH CO] / [TARGET] (2024)

SPA Clause 5.3: "Hell or High Water" Commitment

"Buyer shall take any and all actions, and accept any and all conditions, remedies, or restrictions imposed by any Regulatory Authority, including but not limited to divestitures of assets, behavioural commitments, or restrictions on Buyer's operations, as required to obtain all necessary regulatory approvals. Buyer's obligations under this Clause 5.3 are absolute and unconditional, without regard to the magnitude or impact of such remedies on Buyer or the Target."

Analysis:

• HOHW Level: Level 3 (Absolute, unconditional)
• Limitations: NONE - buyer must accept unlimited remedies
• Reverse Break Fee: £50M (10% of £500M deal value)
• Crown Jewel Protection: NO
• Buyer's Business Protection: NO (buyer's own operations can be restricted)
• Cost Cap: NO

Red Flags:

• ❌ Buyer exposed to unlimited financial and operational risk
• ❌ No protection for buyer's existing business operations
• ❌ Could require divestiture of buyer's core assets (not just Target)
• ❌ No materiality threshold (minor remedy = same obligation as major divestiture)

Assessment: Extremely seller-friendly. Only appropriate where:

1. Buyer is desperate to acquire Target (strategic necessity)
2. Regulatory risk is low (unlikely to require material remedies)
3. Buyer has strong balance sheet to absorb any remedy costs

Note for review: Before the buyer's board approves an absolute commitment of this kind, check it against the directors' general duties (Companies Act 2006, Part 10, Chapter 2, including s.172).

Precedent B: [PE FIRM] / [TARGET] (2023)

SPA Clause 6.2: "Regulatory Endeavours Covenant"

"Buyer shall use all reasonable endeavours to obtain all required regulatory approvals, including acceptance of structural or behavioural remedies, provided that Buyer shall not be obligated to accept remedies that, individually or in the aggregate, would result in a Regulatory Burden. 'Regulatory Burden' means remedies with a financial impact exceeding 5% of the Target's enterprise value (£25M) or requiring divestiture of any business generating more than £10M annual revenue."

Analysis:

• HOHW Level: Level 2 (Modified HOHW with cap)
• Financial Cap: £25M (5% of £500M deal)
• Asset Cap: £10M annual revenue threshold for divestitures
• Reverse Break Fee: £30M (6% of deal value)
• Materiality Threshold: Defined by "Regulatory Burden"

Buyer Protection:

• ✅ Clear financial cap prevents unlimited exposure
• ✅ Asset divestiture limited to non-material businesses
• ✅ "All reasonable endeavours" standard (not absolute)

Seller Protection:

• ✅ Reverse break fee if buyer walks away (£30M)
• ✅ Defined burden threshold (not vague "material adverse effect")

Assessment: Balanced risk allocation. Market-standard for PE transactions where regulatory risk is moderate but quantifiable.

Precedent C: [STRATEGIC BUYER] / [TARGET] (2024)

SPA Clause 7.1: "Regulatory Approvals - Hell or High Water"

"Buyer shall accept all conditions and remedies required by any Regulatory Authority to obtain approval for the Transaction, including divestitures, except that Buyer shall not be required to: (a) Divest or hold separate any of Buyer's [CORE PRODUCT LINES] (the 'Protected Assets'); (b) Accept restrictions on Buyer's business operations outside the Target's business; (c) Accept remedies that would subject Buyer or its directors to criminal liability or civil penalties exceeding £5M."

Analysis:

• HOHW Level: Level 4 (Modified HOHW with specific carve-outs)
• Crown Jewel Protection: YES (Core Product Lines protected)
• Operational Protection: YES (only Target's business can be restricted)
• Penalty Cap: £5M for civil penalties, no criminal liability
• Reverse Break Fee: £40M (8% of deal value)

Buyer Protection:

• ✅ Critical assets explicitly protected (defined list)
• ✅ Buyer's existing operations ring-fenced
• ✅ Cannot be forced to accept criminal liability

Seller Protection:

• ✅ Strong commitment outside carve-outs
• ✅ High reverse break fee (£40M)
• ✅ Narrow carve-outs (only specified assets)

Assessment: Buyer-protective with strong commitment. Best practice for strategic acquisitions where buyer has existing business to protect but is committed to deal.

CURRENT DEAL ANALYSIS

Current SPA Clause 5.5: "All Reasonable Endeavours"

"Buyer shall use all reasonable endeavours to obtain all required regulatory approvals. Buyer shall not be required to accept any remedy that would have a Material Adverse Effect on the Target or the combined business post-completion."

Analysis:

• HOHW Level: Level 1 (Qualified endeavours only)
• No absolute commitment: Buyer can refuse material remedies
• Vague standard: "Material Adverse Effect" undefined
• No reverse break fee: Seller has no financial protection if deal fails
• No obligation to challenge: Buyer not required to challenge adverse decisions

Risk Allocation:

• ❌ Seller bears most regulatory risk (deal may fail if approval denied)
• ❌ Vague MAE standard gives buyer discretion to refuse remedies
• ❌ No break fee means seller gets nothing if buyer walks away
• ❌ Buyer has weak incentive to pursue aggressive regulatory strategy

Comparison to Precedents:

• Much weaker than Precedent A (no absolute commitment)
• Weaker than Precedent B (no defined cap or break fee)
• Weaker than Precedent C (no commitment outside MAE standard)

RECOMMENDATIONS

For Seller:

1. ✏️ Strengthen HOHW provision - Move to Level 2 (Modified HOHW with cap)
2. ✏️ Add reverse break fee - £40-50M (8-10% of deal value) if regulatory approval fails
3. ✏️ Define materiality threshold - Replace vague MAE with specific financial cap (e.g., remedies not exceeding £25M)
4. ✏️ Add obligation to challenge - Require buyer to challenge adverse regulatory decisions
5. ✏️ Timeline commitment - Buyer must submit all required notifications within 30 days of signing

For Buyer:

1. ✏️ Add crown jewel protection - If agreeing to stronger HOHW, protect core assets (Precedent C model)
2. ✏️ Cap financial exposure - Accept remedies up to £25M (5% of deal) but no more
3. ✏️ Ring-fence own business - Ensure restrictions apply to Target only, not buyer's existing operations
4. ✏️ Sunset clause - If approval not obtained within 12 months, either party can terminate (no break fee)

Balanced Approach (Recommended): Adopt Precedent B model (Modified HOHW with defined cap):

Buyer shall accept all structural and behavioural remedies required by any Regulatory Authority to obtain regulatory approval, provided that the aggregate financial impact of such remedies does not exceed £25M (the "Regulatory Cap"). If regulatory authorities require remedies exceeding the Regulatory Cap, Buyer may elect to:
(a) Accept such remedies and proceed to completion; or
(b) Terminate this Agreement and pay Seller a reverse break fee of £40M.

Rationale:

• Seller protected by £25M buyer commitment + £40M break fee
• Buyer exposure capped at maximum £65M (£25M remedies + £40M break fee)
• Clear threshold eliminates dispute over "materiality"
• Balanced risk allocation appropriate for moderate regulatory risk

REGULATORY RISK ASSESSMENT

CMA Merger Clearance (PRIMARY RISK):

• Likely issues: Market concentration in UK SaaS market
• Possible remedies:
  • Behavioural (commitments re: pricing, customer terms): Low cost, likely acceptable
  • Structural (divestiture of overlapping product): £10-20M cost if required
• Probability of an in-depth investigation: Medium

National Security and Investment Act 2021 Approval (SECONDARY RISK):

• Likely outcome: Approval without conditions
• Possible remedies: None expected
• Probability of conditions: Low

Total Expected Regulatory Cost: £5-20M (within proposed £25M cap)

Reverse Break Fee Justification:

• If deal fails due to regulatory issues, seller loses:
  • Opportunity cost (6-12 months out of market)
  • Transaction costs (£2-3M legal/advisory fees)
  • Alternative bidders lost during exclusivity period
• £40M break fee (8% of deal) compensates seller for these risks